The ADA 2019 Standards of Care is now a living document, Living Standards of Care, which provides updates in real time rather than every 12 months. Sections 9 – 11 have been updated with data from Dapagliflozin (Farxiga) Effect on Cardiovascular Events -Thrombosis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial. These sections now incorporate Farxiga’s benefit on heart failure hospitalizations and CDK progression, and safety in moderate renal impairment. Section 10 has been updated with findings from Reduction of Cardiovascular Events with Icosapent Ethyl (Vascepa)-Intervention Trial (REDUCE-IT). ADA recommends Vascepa for triglyceride lowering in persons with diabetes and high atherosclerotic cardiovascular disease risk. To learn more, please click on link below.
Please share your thoughts and subscribe to receive my blogs.
#ada #living #standards #farxiga #vascepa
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.